Immunotherapy applications to glioblastoma represent a new treatment frontier. Antigen-
targeted immunotherapy approaches hold enormous potential to elicit antigen-specific anti …

Malignant gliomas are the most common primary brain cancer diagnosed and still carry a
poor prognosis despite aggressive multimodal management. Despite the continued …

Glioma is the most common primary brain tumor, characterized by a consistently high patient
mortality rate and a dismal prognosis affecting both survival and quality of life. Substantial …

Glioblastoma (GBM) is resistant to multimodality therapeutic approaches. A high burden of
tumor-specific mutant peptides (neoantigens) correlates with better survival and response to …

Glioblastoma (GBM) remains a significant cause of cancer-related mortality in pediatric and
adult patients with limited treatment options. Immunotherapy represents a promising new …

There is a large unmet need for effective therapeutic approaches for glioma, the most
malignant brain tumor. Clinical and preclinical studies have enormously expanded our …

Neoantigens represent promising targets for personalized cancer vaccine strategies.
However, the feasibility of this approach in lower mutational burden tumors like glioblastoma …

Glioblastoma (GBM) remains a disease with a poor prognosis. Unfortunately, over the past
decade, no new treatment options have improved survival in patients beyond the current …

Abstract Purpose of Review This review seeks to inform oncology clinicians and researchers
about the development of novel immunotherapies for the treatment of glioblastoma. An …

Introduction Glioblastoma is a very aggressive cancer with dismal prognosis despite
standard of care including surgical resection, radiation therapy, and chemotherapy. There is …